# China Venture Capital HRVC

> China Venture Capital HRVC is a VC fund in Nanjing backing Information Technology and Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Nanjing, China
- Total investments: 14
- Last investment: Dec 2025
- Lead investor: 21%
- Last updated: Aug 2026
- Website: http://huaruitouzi.cn/

China Venture Capital HRVC is a professional private equity investment management organization that offers consulting.

## Round sizes

| Stage | Round size |
| --- | --- |
| Angel | $60k–$14M |
| Series A | $2.8M–$70M |
| Series B | $2.8M–$14M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Information Technology | 4 | 29% |
| Health Care | 3 | 21% |
| Biotechnology | 3 | 21% |
| SaaS | 1 | 7% |
| Laser | 1 | 7% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Angel | 3 | 21% |
| Series B | 2 | 14% |
| Post-IPO Equity | 2 | 14% |
| Series C | 1 | 7% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Help Therapeutics | Help Stem Cell Innovations Co. Ltd. is the first biotechnology company in China to use iPSC-induced pluripotent stem cell technology to regenerate myocardial, liver, nerve and other tissues and organs. Relying on this core technology, Elp Regenerative Medicine is committed to building a national biological sample bank and cell preparation center,leading the frontier of cell therapy, promoting the clinical transformation of regenerative medicine, and solving the clinically unresolvable degenerative and functional impairment diseases. Reshape human health. |  | Series D | Dec 03, 2025 |  |
| Reprogenix | Reprogenix is a groundbreaking medical technology firm that began with stem cell therapy for diabetes and is dedicated to expanding the use of cell therapy in a wide range of disease areas. | $70.3M | Series A | Nov 20, 2025 |  |
| Yuzhiquan | Yuzhiquan is an optical precision instrument company. It is committed to providing laser direct writing and other high-end optical precision instruments and industry solutions. |  | Series A | Nov 19, 2025 |  |
| Palco | Palco focused on R&D in the field of chemical materials with phenolphthalein type polyaryletherketone (PAEK-a 1 ) as the core product provides products and technical solutions to aerospace, high-speed rail locomotives, automobile industry, electronic information, oil field, energy, medical and other industries. |  | Series A | Oct 31, 2025 |  |
| Zhongke Fifth Era | Zhongke Fifth Era focuses on new technology that builds a material foundation for embodied worlds and multimodal end-to-end large models, as well as intelligent robots. | $14M | Angel | Oct 24, 2025 |  |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China. | $84M | Series C | Oct 14, 2025 |  |
| DIAGENS | DIAGENS is a Hangzhou-based biotechnology firm, providing in-vitro diagnostic (IVD) products and other medical equipment. | $15.7M | Series B | Dec 31, 2021 |  |
| Jyss Bio | Jyss Bio is a developer of disposable bioreactors and peripheral equipment. |  | Series A | May 05, 2021 |  |
| RUHR | RUHR is a security internet of things solutions provider company. | $60K | Angel | Sep 17, 2018 |  |
| KR-VISION | KR-VISION developes software and hardware related to total blindness, low vision and myopia. | $1.4M | Angel | Dec 01, 2016 |  |

10 of 14 investments shown.

## Co-investors
- [Caitong Capital](https://shizune.co/investors/profile/caitong-capital) — VC Fund, 2 deals together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 2 deals together
- [Yinxinggu Capital](https://shizune.co/investors/profile/yinxinggu-capital) — VC Fund, 2 deals together
- [Ameba Capital](https://shizune.co/investors/profile/ameba-capital) — VC Fund, 1 deal together
- [Beicheng Fund](https://shizune.co/investors/profile/beicheng-fund) — VC Fund, 1 deal together
- [Beijing Jiangeng](https://shizune.co/investors/profile/beijing-jiangeng) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Wellness Investors in China](https://shizune.co/investors/wellness-investors-china)
- [Wellness VC Funds in China](https://shizune.co/investors/wellness-vc-funds-china)

## FAQ

### What does China Venture Capital HRVC invest in?

China Venture Capital HRVC invests primarily in Information Technology, Health Care and Biotechnology startups, most often at Series A and Angel stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is China Venture Capital HRVC's check size?

China Venture Capital HRVC typically joins rounds of $60k–$14M at Angel, $2.8M–$70M at Series A and $2.8M–$14M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds China Venture Capital HRVC participates in.

### When did China Venture Capital HRVC last invest?

The most recent investment recorded for China Venture Capital HRVC closed in Dec 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co